Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global...
Hence then, the article about csl and alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases )
Also on site :
- How to watch Republic of Ireland v Israel Nations League in the UK: TV coverage, live stream and kick-off time
- ‘Grey’s Anatomy’ Star Receives Outpouring of Support After Revealing Wife Died From Massive Hemorrhagic Stroke
- Former L’Oréal execs set out to build a $1.2 billion beauty empire. Now all that’s left is Milk Makeup, and its sales just fell 57%